SLIT2 attenuation during lung cancer progression deregulates β-catenin and E-cadherin and associates with poor prognosis

Ruo Chia Tseng, Shih Hua Lee, Han Shui Hsu, Ben Han Chen, Wan Ching Tsai, Ching Tzao, Yi Ching Wang

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Chromosome 4p15.3 is frequently deleted in late-stage lung cancer. We investigated the significance of the SLIT2 gene located in this region to lung cancer progression. SLIT2 encodes an extracellular glycoprotein that can suppress breast cancer by regulating β-catenin. In this study, we examined alterations in the structure or expression of SLIT2, its receptor ROBO1, and β-catenin, along with the AKT/glycogen synthase kinase 3β (GSK3β)/β-transducin repeat-containing protein (βTrCP) pathway in lung cancer cell lines and patients. Low SLIT2 expression correlated with an upward trend of pathological stage and poorer survival in lung cancer patients. Importantly, SLIT2, βTrCP, and β-catenin expression levels predicted postoperative recurrence of lung cancer in patients. Stimulating SLIT2 expression by various methods increased the level of E-cadherin caused by attenuation of its transcriptional repressor SNAI1. Conversely, knocking down SLIT2 expression increased cell migration and reduced cell adhesion through coordinated deregulation of β-catenin and E-cadherin/SNAI1 in the AKT/GSK3β/βTrCP pathway. Our findings indicate that SLIT2 suppresses lung cancer progression, defining it as a novel "theranostic" factor with potential as a therapeutic target and prognostic predictor in lung cancer.

Original languageEnglish
Pages (from-to)543-551
Number of pages9
JournalCancer Research
Volume70
Issue number2
DOIs
Publication statusPublished - Jan 15 2010
Externally publishedYes

Fingerprint

Catenins
Cadherins
Lung Neoplasms
Transducin
Glycogen Synthase Kinase 3
Cell Adhesion
Cell Movement
Glycoproteins
Proteins
Chromosomes
Breast Neoplasms
Recurrence
Cell Line
Survival
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

SLIT2 attenuation during lung cancer progression deregulates β-catenin and E-cadherin and associates with poor prognosis. / Tseng, Ruo Chia; Lee, Shih Hua; Hsu, Han Shui; Chen, Ben Han; Tsai, Wan Ching; Tzao, Ching; Wang, Yi Ching.

In: Cancer Research, Vol. 70, No. 2, 15.01.2010, p. 543-551.

Research output: Contribution to journalArticle

Tseng, Ruo Chia ; Lee, Shih Hua ; Hsu, Han Shui ; Chen, Ben Han ; Tsai, Wan Ching ; Tzao, Ching ; Wang, Yi Ching. / SLIT2 attenuation during lung cancer progression deregulates β-catenin and E-cadherin and associates with poor prognosis. In: Cancer Research. 2010 ; Vol. 70, No. 2. pp. 543-551.
@article{4e15933573574e19b6abdfe9caf12d7b,
title = "SLIT2 attenuation during lung cancer progression deregulates β-catenin and E-cadherin and associates with poor prognosis",
abstract = "Chromosome 4p15.3 is frequently deleted in late-stage lung cancer. We investigated the significance of the SLIT2 gene located in this region to lung cancer progression. SLIT2 encodes an extracellular glycoprotein that can suppress breast cancer by regulating β-catenin. In this study, we examined alterations in the structure or expression of SLIT2, its receptor ROBO1, and β-catenin, along with the AKT/glycogen synthase kinase 3β (GSK3β)/β-transducin repeat-containing protein (βTrCP) pathway in lung cancer cell lines and patients. Low SLIT2 expression correlated with an upward trend of pathological stage and poorer survival in lung cancer patients. Importantly, SLIT2, βTrCP, and β-catenin expression levels predicted postoperative recurrence of lung cancer in patients. Stimulating SLIT2 expression by various methods increased the level of E-cadherin caused by attenuation of its transcriptional repressor SNAI1. Conversely, knocking down SLIT2 expression increased cell migration and reduced cell adhesion through coordinated deregulation of β-catenin and E-cadherin/SNAI1 in the AKT/GSK3β/βTrCP pathway. Our findings indicate that SLIT2 suppresses lung cancer progression, defining it as a novel {"}theranostic{"} factor with potential as a therapeutic target and prognostic predictor in lung cancer.",
author = "Tseng, {Ruo Chia} and Lee, {Shih Hua} and Hsu, {Han Shui} and Chen, {Ben Han} and Tsai, {Wan Ching} and Ching Tzao and Wang, {Yi Ching}",
year = "2010",
month = "1",
day = "15",
doi = "10.1158/0008-5472.CAN-09-2084",
language = "English",
volume = "70",
pages = "543--551",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - SLIT2 attenuation during lung cancer progression deregulates β-catenin and E-cadherin and associates with poor prognosis

AU - Tseng, Ruo Chia

AU - Lee, Shih Hua

AU - Hsu, Han Shui

AU - Chen, Ben Han

AU - Tsai, Wan Ching

AU - Tzao, Ching

AU - Wang, Yi Ching

PY - 2010/1/15

Y1 - 2010/1/15

N2 - Chromosome 4p15.3 is frequently deleted in late-stage lung cancer. We investigated the significance of the SLIT2 gene located in this region to lung cancer progression. SLIT2 encodes an extracellular glycoprotein that can suppress breast cancer by regulating β-catenin. In this study, we examined alterations in the structure or expression of SLIT2, its receptor ROBO1, and β-catenin, along with the AKT/glycogen synthase kinase 3β (GSK3β)/β-transducin repeat-containing protein (βTrCP) pathway in lung cancer cell lines and patients. Low SLIT2 expression correlated with an upward trend of pathological stage and poorer survival in lung cancer patients. Importantly, SLIT2, βTrCP, and β-catenin expression levels predicted postoperative recurrence of lung cancer in patients. Stimulating SLIT2 expression by various methods increased the level of E-cadherin caused by attenuation of its transcriptional repressor SNAI1. Conversely, knocking down SLIT2 expression increased cell migration and reduced cell adhesion through coordinated deregulation of β-catenin and E-cadherin/SNAI1 in the AKT/GSK3β/βTrCP pathway. Our findings indicate that SLIT2 suppresses lung cancer progression, defining it as a novel "theranostic" factor with potential as a therapeutic target and prognostic predictor in lung cancer.

AB - Chromosome 4p15.3 is frequently deleted in late-stage lung cancer. We investigated the significance of the SLIT2 gene located in this region to lung cancer progression. SLIT2 encodes an extracellular glycoprotein that can suppress breast cancer by regulating β-catenin. In this study, we examined alterations in the structure or expression of SLIT2, its receptor ROBO1, and β-catenin, along with the AKT/glycogen synthase kinase 3β (GSK3β)/β-transducin repeat-containing protein (βTrCP) pathway in lung cancer cell lines and patients. Low SLIT2 expression correlated with an upward trend of pathological stage and poorer survival in lung cancer patients. Importantly, SLIT2, βTrCP, and β-catenin expression levels predicted postoperative recurrence of lung cancer in patients. Stimulating SLIT2 expression by various methods increased the level of E-cadherin caused by attenuation of its transcriptional repressor SNAI1. Conversely, knocking down SLIT2 expression increased cell migration and reduced cell adhesion through coordinated deregulation of β-catenin and E-cadherin/SNAI1 in the AKT/GSK3β/βTrCP pathway. Our findings indicate that SLIT2 suppresses lung cancer progression, defining it as a novel "theranostic" factor with potential as a therapeutic target and prognostic predictor in lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=76549117409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76549117409&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-2084

DO - 10.1158/0008-5472.CAN-09-2084

M3 - Article

C2 - 20068157

AN - SCOPUS:76549117409

VL - 70

SP - 543

EP - 551

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -